Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Resource Type

CF Research News

Authors

McColley SA, Konstan MW, Ramsey BW, Stuart Elborn J, Boyle MP, Wainwright CE, Waltz D, Vera-Llonch M, Marigowda G, Jiang JG, Rubin JL

References

J Cyst Fibros. 2018 Aug 23. pii: S1569-1993(18)30719-7. doi: 10.1016/j.jcf.2018.07.011. 

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

Ivacaftor [3]
Lumacaftor [4]
Percent predicted forced expiratory volume in 1 s [5]
Pulmonary exacerbations [6]

Date

Thursday, August 23, 2018

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [7]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/lumacaftorivacaftor-reduces-pulmonary-exacerbations-patients

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-18-00073R2_FINAL_McColley_031018.pdf [2] https://www.ncbi.nlm.nih.gov/pubmed/?term=Lumacaftor/Ivacaftor%20Reduces%20Pulmonary%20Exacerbations%20in%20Patients%20Irrespective%20of%20Initial%20Changes%20in%20FEV1 [3] https://www.ecfs.eu/research-article-keywords/ivacaftor [4] https://www.ecfs.eu/research-article-keywords/lumacaftor [5] https://www.ecfs.eu/research-article-keywords/percent-predicted-forced-expiratory-volume-1%E2%80%AFs [6] https://www.ecfs.eu/research-article-keywords/pulmonary-exacerbations [7] https://www.ecfs.eu/resource-guideline-type/other-guidelines